Despite the apparent failure of nesvacumab, faricimab (Vabysmo) targeting VEGF and angiopoietin-2 was approved for wet AMD and DR based on non-inferiority clinical trials [13,14]. Here, ANGPT2 is linked to wet macular degeneration.